S-100 Protein Relationship with the Survival Rate of Patients with Gastrointestinal Stromal Tumors

Document Type : Original Article (s)

Authors

1 Assistant Professor, Department of pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

2 Professor, Department of pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

3 Student of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

Abstract

Background: Gastrointestinal stromal tumors (GIST) includes a group of mesenchimal tumors. One of the studied issues is the relation between the survival of the patient and protein S-100. We intended to study these types of tumors to understand whether there is any relationship between protein S-100 and survival rate.Methods: In this survival study, 40 patients who with stromal cancer of gastrointestinal tract admitted in AL-Zahra hospital, Isfahan were assessed. These patients were found by studying all the pathological reports recorded in hospital archives.Finding: Forty patients (62.5% male vs 37.5% female) with the mean age of 58.4 ± 16.6 enrolled in study. 12.5% of patients were younger than 40 years old. Protein S-100 was positive just in 17.5% of these patients. 80% of patients have been alive since the end of the study and 20% were dead. The average time of survival from the beginning of diagnosis was 63 ± 4.4 months.Conclusion: Although there are different results about the effect of this protein on prognosis and survival of patients, but protein S-100 is yet considered to be an effective factor on survival and prognosis of these types of tumors and more studies should be carried out to in this field.  

Keywords

References

  1. Rubin BP. Recent progress in the classification of soft tissue tumors: role of genetics and clinical implications. Curr Opin Oncol 2001; 13(4): 256-60.
  2. Pidhorecky I, Cheney RT, Kraybill WG, Gibbs JF. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol 2000; 7(9): 705-12.
  3. Silverberg SG, DeLellis RA, Frable WJ, LiVolsi VA, Wick MR. Silverberg’s Principles and Practice of Surgical Pathology and Cytopathology. 4th ed. Oxeord, UK: Churchill Livingstone; 2005. p. 677-84, 1443-5.
  4. Patel SR, Benjamin RS. Management of perito-neal and hepatic metastases from gastrointestinal stromal tumors. Surg Oncol 2000; 9(2): 67-70.
  5. D'Amato G, Steinert DM, McAuliffe JC, Trent JC. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control 2005; 12(1): 44-56.
  6. Perez D, Demartines N, Meier K, Clavien PA, Jungbluth A, Jaeger D. Protein Protein S100 as prognostic marker for gastrointestinal stromal tumors: a clinicopathological risk factor analysis. J Invest Surg 2007; 20(3): 181-6.
  7. Gunawan B, Bergmann F, Höer J, Langer C, Schumpelick V, Becker H, et al. Biological and clinical significance of cytogenetic abnormalities in low-risk and high-risk gastrointestinal stromal tumors. Hum Pathol 2002; 33(3): 316-21.
  8. Miettinen M, Lasota J, Sobin LH. Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am J Surg Pathol 2005; 29(10): 1373-81.
  9. Nilsson B, Bümming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden. Cancer 2005; 103(4): 821-9.
Journal of Isfahan Medical School
Volume 28, Issue 115 - Serial Number 115
September and October 2011
Pages 969-973

Files

History

  • Receive Date: 06 March 2011
  • Revise Date: 29 April 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics